 LEXINGTON, Mass., Aug. 05, 2020 GLOBE NEWSWIRE -- Kaleido Biosciences, Inc. Nasdaq: KLDO, a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Michael Bonney, Executive Chair, will participate in a fireside chat at the virtual Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 3:30 p.m. ET. A live webcast will be available in the Investors Media section of Kaleidos website at An archived replay will be accessible for 90 days following the event.About Kaleido Biosciences Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies MMTTM. MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the guts existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit Biosciences William Duke, Jr. Chief Financial Officer 617-890-5772 M. Stern Solebury Trout 646-378-2922 R. Mansbach Solebury Trout 646-378-2964 